Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Can Pfizer, Eli Lilly, Bayer AG Or Glaxo Smith And Kline Buy AYTU - CWEB.Com

|About: Aytu BioScience, Inc. (AYTU), BAYRY, CLAR, GSK, LLY, LPCN, PFE

The statistic shows the revenue of Pfizer's (PFE) top product Viagra from 2003 to 2017. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2008, Pfizer's Viagra generated some 1.93 billion U.S. dollars of revenue. Viagra is used primarily to treat erectile dysfunction and pulmonary arterial hypertension. Viagra's patent protection in the U.S. was prolonged until April 2020.

Last year, Pfizer's (PFE) Viagra had worldwide sales of $1.7 billion.

Eli Lilly & Co (LLY) Cialis is also a product for Erectile Dysfunction and has sold Estimated 2016U.S. sales: $1.469 billion U.S 

Bayer AG (OTCPK:BAYRY) and Glaxo Smith Kline (GSK) both have marketed Levitra which also has estimated revenue of Billions of dollars.

Considering that  Aytu Bioscience Inc (OTC:AYTU) is the cheapest in the market for  Erectile Dysfunction Products and has 2 FDA approved medicine and more approvals in the pipeline we believe it could be a potential takeover buy one of the Big Pharma Companies mentioned above.

So the bottom line is that Aytu Bioscience (OTC:AYTU) is trading at it lowest levels with already approved medicine by the FDA versus it's competitors that got rejected by the FDA recently Lipocine's (LPCN) and Clarus (OTC:CLAR).

Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging.

Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress.

Aytu BioScience, Inc. markets ProstaScint that is for use for newly diagnosed high-risk prostate cancer patients and those with recurring prostate cancer. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. For women Aytu BioScience, Inc. has the Fiera personal care device, a hands-free wearable product for women to enhance interest in and physical readiness for sexual activity.

Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging.

Aytu BioScience Receives Market Registration for the MiOXSYS® System for Male Infertility in Mexico.

Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Aytu BioScience, Inc. (OTC:AYTU), is undervalued. 52 Week High traded around $16 before a split.

CWEB Analyst's have Reiterates a Buy Rating for Aytu BioScience, Inc. (OTC:AYTU) , and a Price Target of $10 - $20 within 12 months.

A possible Buy Out for (OTC:AYTU) is strongly possible by a big pharma.

Read Full Article and Videos CWEB.com - Trending News, Blog, Shopping

Chart
AYTU data by YCharts

[object HTMLElement]

Disclosure: I am/we are long AYTU.